<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Nephrotic Syndrome Assessment Algorithm</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, sans-serif;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            min-height: 100vh;
            color: #333;
            line-height: 1.6;
        }

        .container {
            display: flex;
            max-width: 1400px;
            margin: 0 auto;
            padding: 20px;
            gap: 20px;
        }

        .sidebar {
            position: sticky;
            top: 20px;
            width: 280px;
            background: rgba(255, 255, 255, 0.95);
            border-radius: 16px;
            padding: 20px;
            box-shadow: 0 8px 32px rgba(0, 0, 0, 0.1);
            backdrop-filter: blur(10px);
            height: fit-content;
            max-height: calc(100vh - 40px);
            overflow-y: auto;
        }

        .sidebar h2 {
            font-size: 1.2rem;
            color: #4a5568;
            margin-bottom: 15px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .sidebar h2::before {
            content: "üìä";
            font-size: 1.4rem;
        }

        .progress-item {
            display: flex;
            align-items: center;
            padding: 12px;
            margin-bottom: 8px;
            border-radius: 10px;
            cursor: pointer;
            transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
            background: #f7fafc;
            border: 2px solid transparent;
        }

        .progress-item:hover {
            background: #e2e8f0;
            transform: translateX(5px);
        }

        .progress-item.active {
            background: #667eea;
            color: white;
            border-color: #5a67d8;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.4);
        }

        .progress-item.completed {
            background: #48bb78;
            color: white;
        }

        .progress-icon {
            width: 32px;
            height: 32px;
            margin-right: 12px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .progress-text {
            font-weight: 600;
            font-size: 0.95rem;
        }

        .main-content {
            flex: 1;
        }

        .header {
            background: rgba(255, 255, 255, 0.95);
            border-radius: 16px;
            padding: 30px;
            margin-bottom: 25px;
            box-shadow: 0 8px 32px rgba(0, 0, 0, 0.1);
            backdrop-filter: blur(10px);
        }

        .header h1 {
            font-size: 2.5rem;
            color: #2d3748;
            margin-bottom: 10px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .header h1::before {
            content: "ü´Å";
            font-size: 2.8rem;
        }

        .header p {
            color: #4a5568;
            font-size: 1.1rem;
        }

        .card {
            background: rgba(255, 255, 255, 0.95);
            border-radius: 16px;
            margin-bottom: 25px;
            box-shadow: 0 8px 32px rgba(0, 0, 0, 0.1);
            backdrop-filter: blur(10px);
            overflow: hidden;
            transition: all 0.4s cubic-bezier(0.4, 0, 0.2, 1);
        }

        .card:hover {
            transform: translateY(-5px);
            box-shadow: 0 12px 40px rgba(0, 0, 0, 0.15);
        }

        .card-header {
            padding: 25px 30px;
            cursor: pointer;
            display: flex;
            justify-content: space-between;
            align-items: center;
            transition: all 0.3s ease;
        }

        .card-header:hover {
            filter: brightness(0.95);
        }

        .card-header-left {
            display: flex;
            align-items: center;
            gap: 20px;
        }

        .card-icon {
            width: 60px;
            height: 60px;
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 2rem;
            background: rgba(255, 255, 255, 0.3);
        }

        .card-title h2 {
            font-size: 1.5rem;
            margin-bottom: 5px;
        }

        .card-title p {
            font-size: 0.95rem;
            opacity: 0.9;
        }

        .expand-icon {
            font-size: 1.5rem;
            transition: transform 0.3s ease;
        }

        .card.expanded .expand-icon {
            transform: rotate(180deg);
        }

        .card-content {
            max-height: 0;
            overflow: hidden;
            transition: max-height 0.4s cubic-bezier(0.4, 0, 0.2, 1), padding 0.4s ease;
        }

        .card.expanded .card-content {
            max-height: 2000px;
            padding: 0 30px 30px;
        }

        .section {
            margin-bottom: 25px;
        }

        .section h3 {
            font-size: 1.2rem;
            margin-bottom: 15px;
            color: #2d3748;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .badge {
            display: inline-block;
            padding: 4px 12px;
            border-radius: 20px;
            font-size: 0.8rem;
            font-weight: 600;
            margin-left: 10px;
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }

        .badge-red {
            background: #fed7d7;
            color: #c53030;
        }

        .badge-amber {
            background: #fef5e7;
            color: #d69e2e;
        }

        .badge-green {
            background: #c6f6d5;
            color: #276749;
        }

        .checklist {
            list-style: none;
        }

        .checklist li {
            background: #f7fafc;
            padding: 15px 20px;
            margin-bottom: 10px;
            border-radius: 10px;
            border-left: 4px solid #cbd5e0;
            transition: all 0.3s ease;
            display: flex;
            align-items: flex-start;
            gap: 12px;
        }

        .checklist li:hover {
            background: #edf2f7;
            transform: translateX(5px);
        }

        .checklist li::before {
            content: "‚Ä¢";
            color: #667eea;
            font-size: 1.5rem;
            line-height: 1;
            margin-top: -2px;
        }

        .checklist li.urgent {
            border-left-color: #e53e3e;
            background: #fff5f5;
        }

        .checklist li.caution {
            border-left-color: #dd6b20;
            background: #fffaf0;
        }

        .checklist li.stable {
            border-left-color: #38a169;
            background: #f0fff4;
        }

        .grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 20px;
            margin-top: 20px;
        }

        .sub-card {
            background: #f7fafc;
            padding: 20px;
            border-radius: 12px;
            border: 1px solid #e2e8f0;
            transition: all 0.3s ease;
        }

        .sub-card:hover {
            background: #edf2f7;
            transform: translateY(-3px);
        }

        .sub-card h4 {
            color: #2d3748;
            margin-bottom: 10px;
            font-size: 1.1rem;
        }

        .sub-card ul {
            list-style-position: inside;
            color: #4a5568;
        }

        .sub-card li {
            margin-bottom: 5px;
        }

        .info-box {
            background: #ebf8ff;
            border: 1px solid #90cdf4;
            border-radius: 10px;
            padding: 20px;
            margin: 20px 0;
            display: flex;
            align-items: flex-start;
            gap: 15px;
        }

        .info-box::before {
            content: "üí°";
            font-size: 1.5rem;
            flex-shrink: 0;
        }

        .warning-box {
            background: #fff5f5;
            border: 1px solid #feb2b2;
            border-radius: 10px;
            padding: 20px;
            margin: 20px 0;
            display: flex;
            align-items: flex-start;
            gap: 15px;
        }

        .warning-box::before {
            content: "‚ö†Ô∏è";
            font-size: 1.5rem;
            flex-shrink: 0;
        }

        .treatment-flow {
            display: flex;
            flex-direction: column;
            gap: 15px;
        }

        .treatment-step {
            background: #f7fafc;
            padding: 20px;
            border-radius: 12px;
            border-left: 4px solid #667eea;
            position: relative;
        }

        .treatment-step::before {
            content: "‚û§";
            position: absolute;
            left: -10px;
            top: 20px;
            background: #667eea;
            color: white;
            width: 20px;
            height: 20px;
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 0.8rem;
        }

        .footer {
            text-align: center;
            padding: 20px;
            color: rgba(255, 255, 255, 0.8);
            font-size: 0.9rem;
        }

        @media (max-width: 768px) {
            .container {
                flex-direction: column;
                padding: 15px;
            }

            .sidebar {
                width: 100%;
                position: static;
                max-height: none;
            }

            .header h1 {
                font-size: 1.8rem;
            }

            .card-header {
                padding: 20px;
            }

            .card.expanded .card-content {
                padding: 0 20px 20px;
            }
        }

        .fade-in {
            animation: fadeIn 0.6s ease;
        }

        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(20px); }
            to { opacity: 1; transform: translateY(0); }
        }

        .pulse {
            animation: pulse 2s infinite;
        }

        @keyframes pulse {
            0% { box-shadow: 0 0 0 0 rgba(72, 187, 120, 0.7); }
            70% { box-shadow: 0 0 0 10px rgba(72, 187, 120, 0); }
            100% { box-shadow: 0 0 0 0 rgba(72, 187, 120, 0); }
        }

        /* Card-specific colors */
        .card-assessment .card-header {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
        }

        .card-diagnosis .card-header {
            background: linear-gradient(135deg, #f093fb 0%, #f5576c 100%);
            color: white;
        }

        .card-treatment .card-header {
            background: linear-gradient(135deg, #4facfe 0%, #00f2fe 100%);
            color: white;
        }

        .card-followup .card-header {
            background: linear-gradient(135deg, #fa709a 0%, #fee140 100%);
            color: #2d3748;
        }

        .card-followup .card-header .expand-icon {
            color: #2d3748;
        }
    </style>
</head>
<body>
    <div class="container">
        <aside class="sidebar">
            <h2>Progress Tracker</h2>
            <div class="progress-item active" data-step="assessment">
                <div class="progress-icon">üìã</div>
                <div class="progress-text">Assessment</div>
            </div>
            <div class="progress-item" data-step="diagnosis">
                <div class="progress-icon">üî¨</div>
                <div class="progress-text">Diagnosis</div>
            </div>
            <div class="progress-item" data-step="treatment">
                <div class="progress-icon">üíä</div>
                <div class="progress-text">Treatment</div>
            </div>
            <div class="progress-item" data-step="followup">
                <div class="progress-icon">üìà</div>
                <div class="progress-text">Follow-up</div>
            </div>
        </aside>

        <main class="main-content">
            <div class="header">
                <h1>Nephrotic Syndrome Assessment</h1>
                <p>Interactive clinical decision support tool based on BMJ Best Practice Guidelines (April 2025)</p>
            </div>

            <!-- Assessment Card -->
            <div class="card card-assessment expanded" id="assessment">
                <div class="card-header" onclick="toggleCard('assessment')">
                    <div class="card-header-left">
                        <div class="card-icon">üìã</div>
                        <div class="card-title">
                            <h2>Assessment</h2>
                            <p>Initial evaluation and patient history</p>
                        </div>
                    </div>
                    <div class="expand-icon">‚ñº</div>
                </div>
                <div class="card-content fade-in">
                    <div class="section">
                        <h3>Key Diagnostic Criteria <span class="badge badge-amber">Nephrotic Range</span></h3>
                        <div class="info-box">
                            <strong>Definition:</strong> Proteinuria >3.5 g/24 hours (or urine PCR >300 mg/mmol), hypoalbuminaemia <30 g/L, and peripheral oedema. Urine typically contains few cells or casts.
                        </div>
                    </div>

                    <div class="section">
                        <h3>History Taking</h3>
                        <ul class="checklist">
                            <li><strong>Principal symptoms:</strong> Oedema (starts in legs, may progress to anasarca), foamy urine</li>
                            <li class="urgent">
                                <strong>Red flag symptoms:</strong> Rapid deterioration of renal function, severe hypertension, haematuria with red cell casts
                                <span class="badge badge-red">Urgent Referral</span>
                            </li>
                            <li><strong>Malignancy symptoms:</strong> Cough, weight loss, night sweats, change in bowel habit, GI blood loss</li>
                            <li><strong>SLE symptoms:</strong> Rash, mouth ulcers, arthralgias</li>
                            <li><strong>Past medical history:</strong> Diabetes, malignancy, autoimmune disease, viral infections, drug use</li>
                            <li><strong>Family history:</strong> Fabry disease, amyloidosis, other renal diseases</li>
                            <li><strong>Drug history:</strong> NSAIDs, pamidronate, gold, penicillamine, Chinese herbs, mercurial skin-lightening creams</li>
                        </ul>
                    </div>

                    <div class="section">
                        <h3>Physical Examination</h3>
                        <div class="grid">
                            <div class="sub-card">
                                <h4>General Findings</h4>
                                <ul>
                                    <li>Peripheral oedema (legs, periorbital)</li>
                                    <li>Anasarca in severe cases</li>
                                    <li>Muehrcke's lines (white nail banding)</li>
                                    <li>Xanthelasmata from hypercholesterolaemia</li>
                                    <li>Weight gain from oedema (conceals protein loss)</li>
                                </ul>
                            </div>
                            <div class="sub-card">
                                <h4>Disease-Specific Clues</h4>
                                <ul>
                                    <li><strong>SLE:</strong> Malar rash, arthritis <span class="badge badge-amber">Caution</span></li>
                                    <li><strong>Amyloidosis:</strong> Easy bruising, neuropathy</li>
                                    <li><strong>Diabetes:</strong> Retinopathy (fundoscopy) <span class="badge badge-green">Stable</span></li>
                                    <li><strong>Malignancy:</strong> Haem-positive stool</li>
                                </ul>
                            </div>
                        </div>
                    </div>

                    <div class="section">
                        <h3>Initial Investigations <span class="badge badge-green">Essential</span></h3>
                        <div class="grid">
                            <div class="sub-card">
                                <h4>Urine Tests</h4>
                                <ul>
                                    <li>Spot urine protein-to-creatinine ratio (PCR) <br><strong>Diagnostic if >300 mg/mmol</strong></li>
                                    <li>Fresh urine microscopy: lipid droplets, oval fat bodies, Maltese crosses, cholesterol crystals</li>
                                    <li>Urine protein electrophoresis</li>
                                    <li>Few cellular casts (distinguishes from nephritic syndrome)</li>
                                </ul>
                            </div>
                            <div class="sub-card">
                                <h4>Blood Tests</h4>
                                <ul>
                                    <li>Renal function (creatinine, eGFR)</li>
                                    <li>Serum albumin <30 g/L</li>
                                    <li>Lipid profile (elevated total/LDL cholesterol)</li>
                                    <li>FBC, thyroid function</li>
                                </ul>
                            </div>
                        </div>
                    </div>

                    <div class="section">
                        <h3>Specialized Investigations <span class="badge badge-amber">Targeted</span></h3>
                        <ul class="checklist">
                            <li><strong>Autoimmune screen:</strong> ANA, dsDNA, ANCA, complement (C3, C4), cryoglobulins</li>
                            <li><strong>Specific antibodies:</strong> Anti-PLA2R antibody (membranous nephropathy)</li>
                            <li><strong>Paraprotein screen:</strong> Serum free light chains, urine protein electrophoresis with immunofixation</li>
                            <li><strong>Infectious serologies:</strong> Hepatitis B/C, HIV, syphilis (RPR)</li>
                            <li class="caution"><strong>Genetic panel:</strong> Consider in children/young adults with steroid-resistant nephrotic syndrome (SRNS)</li>
                        </ul>
                    </div>

                    <div class="section">
                        <h3>Imaging & Biopsy <span class="badge badge-red">Critical</span></h3>
                        <div class="warning-box">
                            <strong>Renal ultrasound:</strong> Mandatory before biopsy to assess kidney size and exclude contraindications. Small kidneys increase bleeding risk.
                        </div>
                        <div class="info-box">
                            <strong>Renal biopsy:</strong> Required in most adults. In children, may be deferred if steroid-sensitive (presumed MCD). Contraindications include bleeding diathesis, small chronic kidneys, uncontrolled hypertension.
                        </div>
                    </div>
                </div>
            </div>

            <!-- Diagnosis Card -->
            <div class="card card-diagnosis" id="diagnosis">
                <div class="card-header" onclick="toggleCard('diagnosis')">
                    <div class="card-header-left">
                        <div class="card-icon">üî¨</div>
                        <div class="card-title">
                            <h2>Diagnosis</h2>
                            <p>Distinguish underlying causes and differentials</p>
                        </div>
                    </div>
                    <div class="expand-icon">‚ñº</div>
                </div>
                <div class="card-content">
                    <div class="section">
                        <h3>Common Causes <span class="badge badge-amber">Adult vs Child</span></h3>
                        <div class="grid">
                            <div class="sub-card">
                                <h4>üßí Children (1-12 years)</h4>
                                <ul>
                                    <li><strong>Minimal Change Disease (MCD):</strong> 90% of cases <span class="badge badge-green">Steroid Responsive</span></li>
                                    <li><strong>FSGS:</strong> Most common cause of SRNS</li>
                                    <li>Renal biopsy often deferred initially</li>
                                </ul>
                            </div>
                            <div class="sub-card">
                                <h4>üë®‚Äçü¶∞ Adults</h4>
                                <ul>
                                    <li><strong>Focal Segmental Glomerulosclerosis (FSGS):</strong> 35%</li>
                                    <li><strong>Membranous Nephropathy:</strong> 33% (most common in >60 years)</li>
                                    <li><strong>MCD:</strong> 15%</li>
                                    <li><strong>Diabetic Nephropathy:</strong> Most common in longstanding diabetes</li>
                                </ul>
                            </div>
                        </div>
                    </div>

                    <div class="section">
                        <h3>Differential Diagnosis Overview</h3>
                        <div class="treatment-flow">
                            <div class="treatment-step">
                                <h4>Minimal Change Disease <span class="badge badge-green">Good Prognosis</span></h4>
                                <p>Normal light microscopy, podocyte effacement on EM. Often steroid-responsive. May be secondary to Hodgkin's lymphoma or NSAID use.</p>
                            </div>
                            <div class="treatment-step">
                                <h4>Focal Segmental Glomerulosclerosis (FSGS) <span class="badge badge-amber">Variable</span></h4>
                                <p>Primary (idiopathic) vs secondary (HIV, obesity, reflux nephropathy, drugs). Genetic forms in children (NPHS1, NPHS2, LAMB2, WT1).</p>
                            </div>
                            <div class="treatment-step">
                                <h4>Membranous Nephropathy <span class="badge badge-amber">Chronic Course</span></h4>
                                <p>Primary (anti-PLA2R antibodies in 70-80%) vs secondary (malignancy, infections, autoimmune disease). "Spike and dome" appearance on EM.</p>
                            </div>
                            <div class="treatment-step">
                                <h4>Diabetic Nephropathy <span class="badge badge-green">Common</span></h4>
                                <p>Long-standing diabetes, often with retinopathy. Kimmelstiel-Wilson nodules. Rule out non-diabetic renal disease if atypical features.</p>
                            </div>
                        </div>
                    </div>

                    <div class="section">
                        <h3>Key Distinguishing Features</h3>
                        <ul class="checklist">
                            <li class="urgent"><strong>Nephritic vs Nephrotic:</strong>
                                Nephritic = haematuria, red cell casts, renal dysfunction, hypertension
                                <span class="badge badge-red">Different Management</span>
                            </li>
                            <li><strong>Secondary causes:</strong> Malignancy (especially >60 years), infections (HBV, HCV, syphilis, HIV), autoimmune (SLE)</li>
                            <li class="caution"><strong>Amyloidosis:</strong> AL (light-chain) or AA (inflammatory). Investigate for monoclonal paraprotein.</li>
                            <li><strong>Genetic testing:</strong> Consider in SRNS presenting <25 years, especially with family history</li>
                        </ul>
                    </div>

                    <div class="section">
                        <h3>Diagnostic Algorithm <span class="badge badge-green">Stepwise</span></h3>
                        <div class="info-box">
                            <strong>Step 1:</strong> Confirm nephrotic-range proteinuria (PCR >300 mg/mmol) with hypoalbuminaemia<br>
                            <strong>Step 2:</strong> Exclude nephritic features (active urine sediment, renal dysfunction)<br>
                            <strong>Step 3:</strong> Perform serological workup (autoimmune, infections, paraproteins)<br>
                            <strong>Step 4:</strong> Check anti-PLA2R antibodies (may avoid biopsy if positive with preserved renal function)<br>
                            <strong>Step 5:</strong> Renal biopsy in adults (except classic diabetic nephropathy)<br>
                            <strong>Step 6:</strong> Genetic testing if indicated (pediatric SRNS, family history)
                        </div>
                    </div>
                </div>
            </div>

            <!-- Treatment Card -->
            <div class="card card-treatment" id="treatment">
                <div class="card-header" onclick="toggleCard('treatment')">
                    <div class="card-header-left">
                        <div class="card-icon">üíä</div>
                        <div class="card-title">
                            <h2>Treatment</h2>
                            <p>Management strategies by underlying cause</p>
                        </div>
                    </div>
                    <div class="expand-icon">‚ñº</div>
                </div>
                <div class="card-content">
                    <div class="section">
                        <h3>General Management <span class="badge badge-green">All Patients</span></h3>
                        <div class="grid">
                            <div class="sub-card">
                                <h4>Oedema Management</h4>
                                <ul>
                                    <li>Salt restriction (<2g/day sodium)</li>
                                    <li>Loop diuretics (watch for hypovolaemia)</li>
                                    <li>IV albumin + diuretics if severe</li>
                                    <li>Monitor weight daily</li>
                                </ul>
                            </div>
                            <div class="sub-card">
                                <h4>Proteinuria Reduction</h4>
                                <ul>
                                    <li>ACE inhibitors or ARBs (titrate to max tolerated)</li>
                                    <li>Target BP <130/80 mmHg</li>
                                    <li>Reduce intraglomerular pressure</li>
                                    <li>Monitor potassium and renal function</li>
                                </ul>
                            </div>
                        </div>
                    </div>

                    <div class="section">
                        <h3>Specific Immunosuppression</h3>
                        <div class="treatment-flow">
                            <div class="treatment-step">
                                <h4>Minimal Change Disease <span class="badge badge-green">Steroid Responsive</span></h4>
                                <p><strong>Adults:</strong> Prednisolone 1 mg/kg/day (max 60mg) for 4-6 weeks, then taper over 2-3 months. <strong>Children:</strong> 60 mg/m¬≤/day for 4-6 weeks, then alternate-day taper. Consider in children without biopsy if typical features.</p>
                            </div>
                            <div class="treatment-step">
                                <h4>FSGS - Primary <span class="badge badge-amber">Steroid Resistant</span></h4>
                                <p>High-dose steroids may be tried. If resistant: calcineurin inhibitors (tacrolimus/cyclosporine), mycophenolate mofetil, or rituximab. Plasmapheresis if recurrent post-transplant.</p>
                            </div>
                            <div class="treatment-step">
                                <h4>Membranous Nephropathy <span class="badge badge-amber">Risk Stratified</span></h4>
                                <p>Conservative therapy for low risk. Immunosuppression (steroids + cyclophosphamide or rituximab) for high risk (persistent proteinuria, declining GFR, high anti-PLA2R titres). Monitor antibodies.</p>
                            </div>
                            <div class="treatment-step">
                                <h4>Diabetic Nephropathy <span class="badge badge-green">RAAS Blockade</span></h4>
                                <p>Optimize glycaemic control (target HbA1c ~7%), maximize RAAS blockade, SGLT2 inhibitors, statins. No immunosuppression.</p>
                            </div>
                        </div>
                    </div>

                    <div class="section">
                        <h3>Supportive Care <span class="badge badge-green">Essential</span></h3>
                        <ul class="checklist">
                            <li><strong>Lipid management:</strong> Statins (target LDL <2.6 mmol/L)</li>
                            <li class="amber"><strong>Anticoagulation:</strong> Consider if albumin <20 g/L with risk factors (immobility, previous thrombosis, membranous nephropathy)</li>
                            <li><strong>Infection prophylaxis:</strong> Pneumococcal vaccine, influenza vaccine</li>
                            <li><strong>Encourage exercise</strong> to reduce thrombosis risk</li>
                            <li><strong>Dietary:</strong> Protein 0.8-1.0 g/kg/day (avoid high protein), salt restriction</li>
                            <li><strong>Monitoring:</strong> BP, weight, renal function, electrolytes, albumin, lipids</li>
                        </ul>
                    </div>

                    <div class="section">
                        <h3>Complication Management</h3>
                        <div class="grid">
                            <div class="sub-card">
                                <h4>Thromboembolism <span class="badge badge-red">Life Threatening</span></h4>
                                <ul>
                                    <li>Prophylactic anticoagulation if high risk</li>
                                    <li>Therapeutic anticoagulation if thrombosis occurs</li>
                                    <li>More common in membranous nephropathy</li>
                                </ul>
                            </div>
                            <div class="sub-card">
                                <h4>Infection</h4>
                                <ul>
                                    <li>Increased risk due to immunoglobulin loss</li>
                                    <li>Prompt treatment of infections</li>
                                    <li>Consider prophylactic antibiotics post-splenectomy</li>
                                </ul>
                            </div>
                            <div class="sub-card">
                                <h4>Acute Kidney Injury</h4>
                                <ul>
                                    <li>Hypovolaemia from over-diuresis</li>
                                    <li>Ischaemic injury or NSAIDs</li>
                                    <li>May occur in 20-30% of MCD</li>
                                </ul>
                            </div>
                        </div>
                    </div>

                    <div class="section">
                        <h3>When to Refer <span class="badge badge-red">Nephrology</span></h3>
                        <div class="warning-box">
                            <strong>All adults with new nephrotic syndrome</strong> require nephrology referral for biopsy and management. <strong>Children</strong> may be treated empirically but need referral if steroid-resistant, atypical features, or complications.
                        </div>
                    </div>
                </div>
            </div>

            <!-- Follow-up Card -->
            <div class="card card-followup" id="followup">
                <div class="card-header" onclick="toggleCard('followup')">
                    <div class="card-header-left">
                        <div class="card-icon">üìà</div>
                        <div class="card-title">
                            <h2>Follow-up</h2>
                            <p>Monitoring, relapse prevention, and long-term management</p>
                        </div>
                    </div>
                    <div class="expand-icon">‚ñº</div>
                </div>
                <div class="card-content">
                    <div class="section">
                        <h3>Monitoring Schedule <span class="badge badge-green">Regular</span></h3>
                        <div class="grid">
                            <div class="sub-card">
                                <h4>Early Phase (First 6 months)</h4>
                                <ul>
                                    <li>Clinic visits: Every 2-4 weeks</li>
                                    <li>BP, weight, urine dipstick/PCR</li>
                                    <li>Renal function, electrolytes monthly</li>
                                    <li>Albumin and lipids every 3 months</li>
                                </ul>
                            </div>
                            <div class="sub-card">
                                <h4>Stable Phase (>6 months)</h4>
                                <ul>
                                    <li>Clinic visits: Every 3-6 months</li>
                                    <li>BP and urine PCR every visit</li>
                                    <li>Renal function every 3 months</li>
                                    <li>Annual cardiovascular risk assessment</li>
                                </ul>
                            </div>
                        </div>
                    </div>

                    <div class="section">
                        <h3>Relapse Monitoring <span class="badge badge-amber">MCD & FSGS</span></h3>
                        <ul class="checklist">
                            <li class="caution"><strong>High relapse rate:</strong> 50-70% in MCD, variable in FSGS</li>
                            <li><strong>Home monitoring:</strong> Urine dipsticks for protein weekly during weaning</li>
                            <li><strong>Early signs:</strong> Proteinuria, facial/leg swelling, weight gain</li>
                            <li><strong>Action:</strong> Prompt treatment with steroids at first sign of relapse</li>
                            <li><strong>Maintenance therapy:</strong> Consider in frequent relapsers (steroids, MMF, calcineurin inhibitors)</li>
                        </ul>
                    </div>

                    <div class="section">
                        <h3>Long-term Complications <span class="badge badge-amber">Monitor</span></h3>
                        <div class="treatment-flow">
                            <div class="treatment-step">
                                <h4>Cardiovascular Disease</h4>
                                <p>Accelerated atherosclerosis from hyperlipidaemia and hypertension. Annual CV risk assessment, continue statins, strict BP control.</p>
                            </div>
                            <div class="treatment-step">
                                <h4>Chronic Kidney Disease Progression</h4>
                                <p>Monitor eGFR trajectory. Optimize RAAS blockade and risk factors. Prepare for renal replacement therapy if eGFR <20 mL/min.</p>
                            </div>
                            <div class="treatment-step">
                                <h4>Thrombotic Risk</h4>
                                <p>Lifelong increased risk. Continue prophylactic anticoagulation if indicated. Monitor for DVT/PE symptoms.</p>
                            </div>
                            <div class="treatment-step">
                                <h4>Infection Risk</h4>
                                <p>Maintain vaccinations (pneumococcal, influenza). Consider immunoglobulin levels if recurrent infections.</p>
                            </div>
                        </div>
                    </div>

                    <div class="section">
                        <h3>Treatment Withdrawal <span class="badge badge-green">Remission</span></h3>
                        <div class="info-box">
                            <strong>Remission criteria:</strong> Urine protein <0.2 g/day and stable renal function for >6 months. Taper immunosuppression gradually over months to years. Monitor closely for relapse during and after withdrawal.
                        </div>
                        <ul class="checklist">
                            <li><strong>Steroid withdrawal:</strong> Slow taper to avoid adrenal insufficiency</li>
                            <li class="caution"><strong>Calcineurin inhibitor withdrawal:</strong> High relapse risk, taper over >6 months</li>
                            <li><strong>Post-withdrawal:</strong> Monthly monitoring for first 6 months</li>
                        </ul>
                    </div>

                    <div class="section">
                        <h3>Patient Education <span class="badge badge-green">Essential</span></h3>
                        <div class="grid">
                            <div class="sub-card">
                                <h4>Key Topics</h4>
                                <ul>
                                    <li>Signs of relapse (swelling, foamy urine)</li>
                                    <li>Medication adherence (especially steroids)</li>
                                    <li>Salt restriction importance</li>
                                    <li>Vaccination needs</li>
                                    <li>Thrombosis prevention (exercise, hydration)</li>
                                    <li>When to seek urgent help</li>
                                </ul>
                            </div>
                            <div class="sub-card">
                                <h4>Lifestyle Advice</h4>
                                <ul>
                                    <li>Balanced protein intake (0.8-1.0 g/kg)</li>
                                    <li>Low sodium diet (<2g/day)</li>
                                    <li>Regular exercise</li>
                                    <li>smoking cessation</li>
                                    <li>Avoid NSAIDs</li>
                                    <li>Weight monitoring</li>
                                </ul>
                            </div>
                        </div>
                    </div>

                    <div class="section">
                        <h3>Prognosis <span class="badge badge-amber">Variable</span></h3>
                        <div class="grid">
                            <div class="sub-card">
                                <h4>Favorable Outcomes</h4>
                                <ul>
                                    <li>Minimal Change Disease: Good long-term prognosis</li>
                                    <li>Steroid-responsive cases: 80% remission</li>
                                    <li>Complete remission: Best renal survival</li>
                                </ul>
                            </div>
                            <div class="sub-card">
                                <h4>Poor Prognostic Factors</h4>
                                <ul>
                                    <li>FSGS with collapsing variant</li>
                                    <li>Persistent heavy proteinuria (>6 months)</li>
                                    <li>Renal dysfunction at presentation</li>
                                    <li>Hypertension</li>
                                    <li>Tubulointerstitial fibrosis on biopsy</li>
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>

        </main>
    </div>

    <div class="footer">
        <p>Based on BMJ Best Practice Guidelines (April 2025) | For educational purposes only | Not a substitute for clinical judgement</p>
    </div>

    <script>
        // Card toggle functionality
        function toggleCard(cardId) {
            const card = document.getElementById(cardId);
            const isExpanded = card.classList.contains('expanded');
            
            // Close all cards
            document.querySelectorAll('.card').forEach(c => {
                c.classList.remove('expanded');
            });
            
            // Open clicked card if it wasn't already open
            if (!isExpanded) {
                card.classList.add('expanded');
                scrollToCard(card);
            }
            
            updateProgress();
        }

        function scrollToCard(card) {
            setTimeout(() => {
                card.scrollIntoView({ behavior: 'smooth', block: 'start' });
            }, 100);
        }

        // Progress sidebar functionality
        function updateProgress() {
            const cards = ['assessment', 'diagnosis', 'treatment', 'followup'];
            let foundActive = false;
            
            cards.forEach((cardId, index) => {
                const card = document.getElementById(cardId);
                const progressItem = document.querySelector(`[data-step="${cardId}"]`);
                
                if (card.classList.contains('expanded')) {
                    progressItem.classList.add('active');
                    progressItem.classList.remove('completed');
                    foundActive = true;
                } else if (!foundActive) {
                    progressItem.classList.remove('active');
                    progressItem.classList.add('completed');
                } else {
                    progressItem.classList.remove('active', 'completed');
                }
            });
        }

        // Progress item click handler
        document.querySelectorAll('.progress-item').forEach(item => {
            item.addEventListener('click', () => {
                const step = item.dataset.step;
                const card = document.getElementById(step);
                
                // Close all cards
                document.querySelectorAll('.card').forEach(c => {
                    c.classList.remove('expanded');
                });
                
                // Open selected card
                card.classList.add('expanded');
                scrollToCard(card);
                updateProgress();
            });
        });

        // Auto-expand first card on load
        window.addEventListener('DOMContentLoaded', () => {
            updateProgress();
        });

        // Add smooth reveal animations on scroll
        const observer = new IntersectionObserver((entries) => {
            entries.forEach(entry => {
                if (entry.isIntersecting) {
                    entry.target.classList.add('fade-in');
                }
            });
        }, {
            threshold: 0.1
        });

        // Observe all cards
        document.querySelectorAll('.card').forEach(card => {
            observer.observe(card);
        });
    </script>
</body>
</html>